A Phase 2 interventional study of Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging and Glucose-loaded ¹⁸F-FDG PET Myocardial Metabolic Imaging in Ischemic Cardiomyopathy and Heart Failure, sponsored by Sinotau Pharmaceutical Group. Recruiting at 3 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Sinotau Pharmaceutical Group · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 375 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.
Among the 375 studies in Heart Failure with a site in China, this one is the 201st largest by planned enrollment of the 246 interventional ones that give a count, is one of 36 that started in 2025, is one of 22 in phase 2, reaches primary completion later than 82 of the 181 other live ones, and was the 327th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →162 of the 375 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 65+
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+ · Healthy volunteers
AstraZeneca · Sites in China, United States, Argentina and 29 more countries
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
Tasly Pharmaceutical Group Co., Ltd · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
375 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 44 · Phase 3 49 · Phase 4 29
First in 1983; this study’s year is marked. 36 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 127 across the 246 interventional studies, 540 across the 129 observational. Of the 115 that completed or were terminated, 33 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 375 have an industry lead sponsor. The 10 most frequent:
Sinotau Pharmaceutical Group is the lead sponsor of 17 studies on the registry; 5 are open to participants now.
Sinotau Pharmaceutical Group has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
46 of the studies in Heart Failure with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT07496372Phase 3HELP Therapeutics Co., Ltd.A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV) | 2027-06-30 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06927440Shanghai Jiao Tong University School of MedicineNational Multicenter Registry for Pediatric End-Stage Heart Failure in China | 2026-11-30 |
Add all 46 to your calendar (.ics) → With an account.
Among the 375 studies in Heart Failure with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, multicenter, randomized, open-label, parallel-controlled Phase IIb study to investigate the diagnostic-prognostic utility of XTR003 Injection integrated with 18F-FDG as an exploratory clinical trial. A total of 40-60 patients will be enrolled and randomized into two study groups as: fasting XTR003/18F-FDG group and glucose-loaded group at a 1:1 ratio. Each group will receive resting myocardial perfusion imaging (MPI) combined with metabolic PET imaging to evaluate myocardial metabolic activity and myocardial viability. Segmental perfusion abnormality, metabolic activity and myocardial viability will be analyzed according to the standard approaches in Nuclear Cardiology. Regional and global left ventricular function will be assessed with cardiac MRI and echocardiography prior to and post the completion of full revascularization within 6-month time point. A repeated resting MPI will also be performed to assess the improvement of perfusion abnormality.
All study subjects will undergo 6 months follow-up for major adverse cardiac events (MACE).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fasting XTR003 and ¹⁸F-FDG PET combined with myocardial metabolic imaging
Drug: Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging
Glucose-modulated ¹⁸F-FDG PET Myocardial Metabolic Imaging
Drug: Glucose-loaded ¹⁸F-FDG PET Myocardial Metabolic Imaging
Fasting XTR003 / ¹⁸F-FDG PET myocardial metabolic imaging
Glucose loaded ¹⁸F-FDG PET Myocardial Metabolic Imaging
the sensitivity and specificity of the experimental group and control group
Using the recoverable left-ventricular wall motion abnormality at 6 months post full revascularization as the reference standard to study the sensitivity and specificity of myocardial viability for predicting functional recovery in the experimental group and control group.
Time frame: 6 months
Myocardial perfusion-metabolism imaging parameters (segmental level)
include the following three items: 1. summed rest score 2. summed FDG score 3. summed rest score minus summed FDG score
Time frame: 6 months
Changes in left ventricular function parameters measured by cardiac magnetic resonance before and after revascularization
Left ventricular ejection fraction (LVEF, %)
Time frame: 6 months
Changes in left ventricular function parameters measured by cardiac magnetic resonance before and after revascularization
Left ventricular end-diastolic diameter (LVEDD)
Time frame: 6 months
Changes in left ventricular function parameters measured by cardiac magnetic resonance before and after revascularization
Left ventricular end-systolic diameter (LVESD)
Time frame: 6 months
Changes in left ventricular function parameters measured by cardiac magnetic resonance before and after revascularization
Left ventricular end-diastolic volume (LVEDV, mL)
Time frame: 6 months
Changes in left ventricular function parameters measured by cardiac magnetic resonance before and after revascularization
Left ventricular end-systolic volume (LVESV, mL)
Time frame: 6 months
Changes in New York Heart Association Functional Classification (NYHA)
Time frame: 6 months
Duration Required for PET Myocardial Metabolic Imaging in the Two Groups (min)
Time frame: day 1
PET Myocardial Metabolic Imaging Quality
Time frame: day 1
Resting MPI of perfusion abnormality
Time frame: 6 months
Major adverse cardiac events (MACE)
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's planned 12 months is below that.
Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.
Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sinotau Pharmaceutical Group